Betrixaban

• Venous Thromboembolism Prevention
• DVT Prophylaxis
• Pulmonary Embolism Prevention
• Hospital-Acquired Blood Clots

Betrixaban (brand name Bevyxxa) is an oral direct factor Xa inhibitor that was approved specifically for extended-duration prophylaxis of venous thromboembolism (VTE) in acutely ill, hospitalized medical patients with restricted mobility. Although the manufacturer discontinued U.S. distribution in 2020, betrixaban remains a useful reference point for understanding the factor Xa inhibitor class and the role of extended thromboprophylaxis after hospital discharge — a transition period that historically carried meaningful clot risk with no convenient oral solution.

Mechanism of Action

Betrixaban directly and reversibly inhibits the active site of factor Xa, the serine protease that converts prothrombin to thrombin in the final common pathway of the coagulation cascade. By blunting thrombin generation, it suppresses the conversion of fibrinogen to fibrin and prevents clot propagation. Unlike unfractionated heparin and enoxaparin, it does not require antithrombin as a cofactor, and unlike warfarin it produces a predictable anticoagulant effect without the need for routine INR monitoring.

Betrixaban has the longest half-life among oral factor Xa inhibitors at roughly 19–27 hours, which supports once-daily dosing and a relatively flat plasma profile — characteristics that may reduce trough variability in patients with marginal compliance. It is minimally metabolized by cytochrome P450 enzymes, with most clearance occurring through biliary excretion as unchanged drug. The drug is, however, a substrate for P-glycoprotein, which underlies its key clinically relevant drug interactions. There is no specific reversal agent labeled for betrixaban, although andexanet alfa may produce some restoration of factor Xa activity if catastrophic bleeding occurs.

Clinical Use

Betrixaban occupies a narrow niche compared with other direct oral anticoagulants. Its sole FDA-approved indication was VTE prophylaxis for the duration of acute medical hospitalization plus an extended period of 35–42 days after discharge — a setting in which the prior standard of care had been short-course parenteral enoxaparin during admission only. The pivotal APEX trial showed that extended oral betrixaban modestly reduced symptomatic deep venous thrombophlebitis, pulmonary embolism, and VTE-related death compared with standard-duration enoxaparin in a high-risk subgroup, although the primary endpoint just barely missed statistical significance in the overall population.

For other indications — stroke prevention in atrial fibrillation, treatment of established VTE, post-operative orthopedic prophylaxis, or secondary prevention after acute coronary syndrome — the better-studied agents apixaban, rivaroxaban, edoxaban, and dabigatran are preferred. In current practice, where betrixaban is unavailable, an extended course of low-dose rivaroxaban (10 mg daily) following the MARINER trial framework is one option, although the broader question of whether to extend prophylaxis at all in medical patients remains debated. The CDC's overview of DVT and pulmonary embolism is useful patient orientation.

How to Take It

The regimen is a single 160 mg oral loading dose, followed by 80 mg once daily for 35–42 days. The drug is taken with food, which improves and stabilizes absorption — fasting administration reduces exposure considerably. The same time each day works best because the consistent peak-to-trough profile depends on regular intervals.

If a dose is missed, it is taken as soon as remembered the same day; doses are never doubled. Capsules are stored at room temperature in their original packaging. Patients should be specifically counseled not to begin a new bottle of any over-the-counter NSAID, aspirin, or fish oil supplement without first checking with the prescriber, since concurrent antiplatelet effects markedly increase bleeding risk. Acetaminophen at appropriate doses is the preferred first-line analgesic.

Dental cleanings and minor dermatologic procedures usually proceed without holding anticoagulation, but the prescriber should be informed in advance. Any planned surgery, colonoscopy with anticipated polypectomy, joint injection, or epidural injection requires a coordinated drug hold. The MedlinePlus page for DVT and our coverage of clot risk in stroke prevention in atrial fibrillation provide additional context.

Monitoring and Follow-Up

No routine coagulation monitoring is required, which is one of the principal advantages over warfarin. Baseline labs should include a complete blood count, creatinine with calculated CrCl, and liver enzymes — see understanding blood work lab panels for orientation. Patients with severe renal impairment (CrCl 15–30 mL/min) require dose reduction to a 80 mg load followed by 40 mg daily, and the same reduction applies to patients on strong P-glycoprotein inhibitors regardless of renal function.

Hemoglobin and renal function should be rechecked at any meaningful change in clinical status — new dehydration, contrast administration, or an acute illness can shift drug exposure considerably. Stool guaiac and occult blood testing are reasonable if any symptoms suggest occult GI bleeding. The FDA's prescribing information remains accessible at the FDA drug label database.

Special Populations

Betrixaban is not recommended in end-stage renal disease or dialysis and should be avoided in moderate or severe hepatic impairment due to limited data. Concomitant strong P-glycoprotein inhibitors (amiodarone, verapamil, ketoconazole, clarithromycin, certain HIV antivirals) require the reduced dose, and concurrent use is best avoided altogether in patients with severe renal impairment. Pregnancy data are limited; anticoagulation in pregnancy generally relies on low-molecular-weight heparin such as enoxaparin because direct oral anticoagulants cross the placenta and DOAC fetal safety data are sparse.

The drug should be discontinued at least 72 hours before any procedure carrying meaningful bleeding risk, and longer in patients with renal impairment. Neuraxial anesthesia carries a risk of spinal hematoma resulting in permanent neurologic injury; the timing of catheter placement and removal must be coordinated carefully with the prescriber and the anesthesia team. Older adults — the patient group most likely to need extended VTE prophylaxis — also have the highest risk of bleeding complications, and any decision to anticoagulate should reflect a frank discussion of competing risks.

Lifestyle and Supportive Care

For patients on extended VTE prophylaxis after hospital discharge, lifestyle measures complement pharmacologic anticoagulation. Early ambulation is the single most powerful nondrug intervention — even slow walks several times daily during recovery markedly reduce stasis in the deep veins of the calves. Patients who must remain seated for prolonged periods should perform regular ankle pumps and calf muscle activations.

Graduated compression stockings can supplement, although not replace, anticoagulation in patients at very high risk; properly fitted thigh-high or knee-high stockings of moderate compression help maintain venous return. Adequate hydration matters because dehydration thickens blood and slows venous flow — a particular issue for older adults whose thirst response is blunted and for patients in hot climates such as Florida. Air travel should be approached with thoughtful planning during the post-hospital VTE risk window: aisle seats, hourly walks, calf exercises during sitting, and adequate fluids reduce the additive risk of immobility.

Weight management, smoking cessation, and avoidance of estrogen-containing oral contraceptives or hormone therapy in patients with prior VTE further reduce future event risk. Patients with active cancer have a particularly high baseline VTE rate, and prophylaxis decisions should be coordinated with oncology since cancer treatments themselves modulate clot risk both up and down. Finally, family members of patients on any anticoagulant should know basic bleeding control measures — direct pressure, elevation, ice — and when to call for emergency help. Patients should also be given written information about their anticoagulant including the drug name, dose, indication, and the date prophylaxis is scheduled to end, so any clinician they see during the prophylaxis window has clear information rather than relying on memory or assumption. A medical alert bracelet or wallet card identifying the patient as on an oral anticoagulant is a worthwhile precaution.

When to Contact Your Doctor

Seek emergency care for any signs of major bleeding — severe headache, sudden weakness or numbness suggesting a stroke, vomiting blood or material that resembles coffee grounds, black or tarry stools, bright red rectal bleeding, coughing up blood, or any uncontrolled bleeding from a cut. Unusual bruising without clear cause, prolonged nosebleeds, pink, red, or brown urine, and new back pain after spinal anesthesia all warrant prompt evaluation. Any fall, particularly with a head strike, while on anticoagulation should be reported even if the patient feels well.

If you have questions about betrixaban, alternative anticoagulants, or your overall clot prevention strategy, our team at Zimmer Medical Group can help — contact us or schedule a visit.